Find us on:


Research Type
Reported as
Publication Type
Sort By
Total: 163
Low-dose naltrexone-induced remission in Hailey–Hailey disease maintained in remission with topical combination of ketamine and diphenhydramine
Research Type Human Reported as Case Report/Series/Restrospective Study Date September 24, 2019 Authors Sidharth Sonthalia, Mahima Agrawal, Ankur Talwar, Mohamad Goldust Institution Mazandaran University of Medical Sciences; HIMS Institute, LHMC and Associated Hospitals, Skinnocence Skin Clinic and Research Centre Disease Hailey-Hailey
Recent anecdotal evidence suggests that oral low-dose naltrexone (LDN) is effective for Hailey–Hailey disease (HHD) but suffers the limitation of immediate relapse following cessation of the medication. With lack of safety data on long-term administration of LDN, we explored the utility of a topical diphenhydramine/ketamine (DK) cream in maintaining the remission achieved with LDN. A 42-year-old male with treatment-refractory HHD remitted with 5 mg naltrexone/day but relapsed on stopping the d...
Hailey-Hailey disease treated successfully with naltrexone and magnesium.
Research Type Human Reported as Case Report/Series/Restrospective Study Date August 29, 2019 Authors Ali Alajmi, Abdulhadi Jfri, Audrey Lovett Institution McGill University Health Centre Disease Hailey-Hailey
Hailey-Hailey disease (HHD), or benign familial pemphigus, is an autosomal dominant genodermatosis that usually presents between the second and fourth decades of life as painful blisters and erosions in the intertriginous areas. It is characterized by a remitting, relapsing course, and recurrent episodes of superinfection. HHD is caused by mutations in the ATP2C1 gene. Although HHD is not life threatening, it has a significant negative impact on patient quality of life. Many treatments exist, b...
Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias?
Research Type Human Reported as Opinion Date August 15, 2019 Authors Violeta Duarte Tortelly, Taynara de Mattos Barreto, Larissa Starling de Albuquerque Fernandes, Bruno Eduardo Morais Nunes, Daniel Fermandes Melo Institution State University of Rio de Janeiro, Marcilio Dias Naval Hospital Disease Alopecia
Naltrexone is a competitive antagonist of μ, k and γ opioid receptors, used for treatment of alcoholism and opioid addiction. Low-dose naltrexone (LDN) is defined as daily doses ranging from 1mg to 5mg. This is purported to have a paradoxical effect that leads to an increase in endogenous opioids, including beta-endorphins, which have anti-inflammatory properties. These mechanisms may also justify their possible role in the treatment of inflammatory conditions. The aim of this article is to di...
Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy
Research Type Human Animal Lab (in-vitro) Reported as Review Date August 09, 2019 Authors Ruizhe Wang, Yi Zhang, Fengping Shan Institution China Medical University Disease Cancer (general)
 Endogenous opioids are neuro-peptides with multifunctional properties. Historically, opioids are used to mediate pain; however, excess opiate consumption can lead to addiction. One endogenous opioid, methionine enkephalin (MENK), was reported to modulate cell growth, MENK was identified as an opioid growth factor (OGF) that interacts with the OGF receptor (OGFr) and regulates cell proliferation. Further, opioid antagonists, including naltrexone and naloxone are widely used to reverse drug and ...
Naltrexone for the Treatment of Darier and Hailey-Hailey Diseases.
Research Type Human Reported as Review Date July 01, 2019 Authors A Jfri, IV Litvinov, E Netchiporouk Institution McGill University Disease Darier Disease, Hailey-Hailey
Darier (DD) and Hailey-Hailey (HHD) diseases are both genodermatoses caused by defective calcium transport and homeostasis. DD is caused by a mutation of the ATPA2A gene and HHD by a mutation of the ATP2C1 gene. Clinically, the former is characterized by itchy, painful macerations with red-brownish papules in a seborrheic distribution; the latter manifests with painful blisters that rupture, leaving erosions in intertriginous areas. Treatment options for both conditions are limited and include t...
Low-dose naltrexone: a unique treatment for amyopathic dermatomyositis
Research Type Human Reported as Case Report/Series/Restrospective Study Date June 01, 2019 Authors Albert P. Manudhane, Kory P. Schrom, Harib H. Ezaldein, James A. Armile Institution Brown University Warren Alpert Medical School, University Hospitals Cleveland Medical Center, Case Western Reserve University, Lake Erie College of Osteopathic Medicine Disease Amyopathic Dermatomyositis
Gottron papules, a heliotrope rash, scalp and extremity erythema, pruritus, and fatigue are the characteristic signs and symptoms of amyopathic dermatomyositis (ADM). Amyopathic dermatomyositis is considered a distinct entity from dermatomyositis (DM) because the characteristic muscle weakness and muscle enzyme elevations of DM are absent in ADM. With respects to treatment, ADM treatments have traditionally included topical corticosteroids and/or systemic immunosuppressants and immunomodulators....
Low-dose naltrexone therapy in benign chronic pemphigus (Hailey-Hailey disease): a case series.
Research Type Human Reported as Case Report/Series/Restrospective Study Date April 16, 2019 Authors C. Riquelme-Mc Loughlin, J. Riera-Monroig, D. Morgado-Carrasco, P. Giavedoni, S. Podlipnik, P. Iranzo, J.M. Mascaró Jr Institution University of Barcelona Disease Hailey-Hailey
University of Barcelona physicians studied the effect of low dose naltrexone (LDN) on 14 patients with Hailey-Hailey disease (HDD), also known as benign chronic pemphigus. The authors suggest that future studies be done to determine if certain genetic profiles are associated with favorable responses to LDN....
Use of low-dose naltrexone in the treatment of severe Hailey-Hailey disease: one case report.
Research Type Human Reported as Case Report/Series/Restrospective Study Date April 08, 2019 Authors María Garayar Cantero, Marina Canseco Martín, Ángel Aguado García, Pilar Manchado López Institution Hospital Clínico Universitario de Valladolid Disease Hailey-Hailey
INTRODUCTION: Hailey-Hailey disease (HHD) or chronic benign familial pemphigus is an autosomal dominant genodermatosis with complete penetrance characterized by painful vesicles, erosions and macerated intertriginous skin. CASE REPORT: We present a 66-year-old woman with a personal 35-year history of pruritic recurrent vesicles and erosions in both axillae and inguinal folds. HHD was confirmed by cutaneous biopsy. Past treatments had failed, including topical corticosteroids, antibiotics and ...
Low Dose Naltrexone for Neuropathic Pain Related to an Electrical Burn Injury: A Case Study
Research Type Human Reported as Case Report/Series/Restrospective Study Date April 01, 2019 Authors M. Cowling, M. Poliak-Tunis Institution University of Wisconsin Disease Chronic Pain
A 36- year old male with a past history significant for bipolar disorder, depression, and PTSD presented to UW Pain Clinic for management of ongoing pain related to an electrical burn injury (4.5%) to the left hand and flank sustained in August 2016. He underwent a skin graft for the burn six months later and has experienced difficulties with his pain since. During the consult, the patient described his pain as a burning, tingling sensation over the left flank and hand. He also experiences sharp...
Low-Dose Naltrexone in the Treatment of Fibromyalgia: A Retrospective Analysis
Research Type Human Reported as Case Report/Series/Restrospective Study Date April 01, 2019 Authors Jordan Wulz Institution Ascension Wisconsin Center for Pain Management, Concordia University Wisconsin Disease Fibromyalgia
The first scientific reference of fibromyalgia as a medical disorder occurred in 1981. Since then, pain management experts have continuously debated diagnosis criteria, potential pathologies, and viable treatment options due to the complex nature of the disease. For both patient and clinician, the efficacy of current pharmacologic treatments can be frustrating. The clinical benefit of medications is often modest at best. In fact, the 2016 European League Against Rheumatism (EULAR) guideline for ...